News_en

YC Biotech and Xinmei Community Healthcare Group Jointly Hold Signing Meeting

Leave a Comment / News_en / yc89192889

YC Biotech, the exclusive distributor of EG BioMed’s DNA methylation breast cancer detection technology, recently introduced this groundbreaking diagnostic tool to medical professionals at Xinmei Community Health Care Group in Tucheng. This advanced technology provides a more precise and innovative approach to early breast cancer detection, enhancing diagnostic accuracy and post-treatment monitoring. Developed by EG […]

YC Biotech and Xinmei Community Healthcare Group Jointly Hold Signing Meeting Read More »

MATRIXLabs Medical and YC Biotech Sign Memorandum of Cooperation, Advancing Medical Device Innovation

Leave a Comment / News_en / yc89192889

Taipei City – May 12, 2023 MATRIXLabs Medical and YC Biotech have announced the signing of a memorandum of cooperation, marking a significant step toward enhancing the production efficiency and market adoption of laparoscopic suture knotting devices. MATRIXLabs Medical, a company dedicated to cutting-edge medical device development, has introduced an innovative laparoscopic suture knotting device

MATRIXLabs Medical and YC Biotech Sign Memorandum of Cooperation, Advancing Medical Device Innovation Read More »

YC Biotech Partners with Neogence Group’s Getraising Biotechnology to Enter the Beauty and Skincare Market

Leave a Comment / 英文, News_en / yc89192889

Taipei City – April 12, 2023 YC Biotech, a global leader in advanced biotechnology research and development, has officially partnered with Getraising Biotechnology, a premier cosmetics and skincare OEM manufacturer under the Neogence Group. The two companies have formalized their collaboration by signing a memorandum of cooperation, marking the beginning of a long-term strategic alliance.

YC Biotech Partners with Neogence Group’s Getraising Biotechnology to Enter the Beauty and Skincare Market Read More »

YC Biotech and Xinmei Community Healthcare Group Jointly Hold Signing Meeting

MATRIXLabs Medical and YC Biotech Sign Memorandum of Cooperation, Advancing Medical Device Innovation

YC Biotech Partners with Neogence Group’s Getraising Biotechnology to Enter the Beauty and Skincare Market

🔸Contains fully absorbable nanomolecular exosomes (stem cell grade)

🔸Provides deep tissue regeneration and revitalization

🔸Incorporates a curated assortment of tripeptides and tetrapeptides to effectively combat wrinkles, dry skin, and inflammation

🔸Utilizes high molecular weight hyaluronic acid for prolonged hydration

🔸Enriched with hydrolyzed marine collagen to enhance skin firmness and elasticity

🔸Completely absorbable stem cell grade nanomolecular exosomes

🔸An elixir for rapid restoration of skin

🔸A soothing, moisture retaining, anti-aging concoction

🔸Contains fully absorbable nanomolecular exosomes (stem cell grade)

🔸Provides deep tissue regeneration and revitalization

🔸Incorporates a curated assortment of tripeptide & tetrapeptides to effectively combat wrinkling, dry skin and inflammation

The complexity and demands of protocols have increased in recent years.

That complexity is putting a burden on patients and investigators alike and can heavily impact patient enrollment rates.

Yet amending protocols mid-stream will noticeably increase the time and cost of the development program with no guarantee of outcome improvement.

All stages of the drug development life cycle, after drug discovery involve CMC.

After clinical trials the scale-up process must ensure that the larger batches of product are the same and meet the same specifications as the drug tested in the clinical trials, and after the manufacturing process is qualified, lot release and in-process testing will continue to take place.

試驗計劃的複雜性和要求近年來不斷增加，使受試者和研究人員帶來了負擔，也可能影響受試者的參與率。然而，中途修改試驗計劃將增加開發計劃的時間和成本，並不能保證結果的改善。

透過我們的專業支持，客戶可以確保其藥物開發過程順利進行，並符合相關的法規和品質標準，從而實現成功的藥物上市。

PK樣本分析

快速PK篩選

ELISA 測試

最佳給藥方案分析